Tumor Board: How The Experts Approach Personalized Care Plans in ER-Positive Breast Cancer
View More
Community Practice Connections™: Translating Recent Evidence on CAR T-Cell Therapy to the Real-World Management of Lymphoid Malignancies
View More
7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards
View More
CAR T-Cell Therapy in Multiple Myeloma: Key Considerations for Patient Selection, Transplant, and Applying Recent Data
View More
Evolving Paradigms in Transplant-Related CMV Prevention and Management: Setting Foundations for Improved Patient Outcomes
View More
Evolving Paradigms in Transplant-Related CMV Prevention and Management: Setting Foundations for Improved Patient Outcomes
View More
Optimizing ASCT in Patients With Multiple Myeloma and Non-Hodgkin Lymphoma Through Stem Cell Mobilization Techniques
View More
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
View More
Epcoritamab Regimen Yields Remission in High-Risk R/R Follicular Lymphoma
June 7th 2023The responses to epcoritamab plus rituximab/lenalidomide for patients with relapsed/refractory follicular lymphoma appear comparable between those with and without disease progression within 24 months of first-line chemotherapy in the phase 1/2 EPCORE NHL-2 trial.
Liso-Cel Yields Encouraging Responses in Relapsed/Refractory CLL/SLL
June 7th 2023Treatment with lisocabtagene maraleucel correlates with a reduction in CD19-positive cells in responders and patients with stable disease among those with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the phase 1/2 TRANSCEND CLL 004 trial.
Tumor Treating Fields Plus SOC May Benefit OS in Metastatic NSCLC
June 7th 2023The results of the phase 3 LUNAR trial evaluating tumor treating fields plus standard-of-care therapies among patients with metastatic non–small cell lung cancer are “encouraging,” according to an expert from Winship Cancer Institute of Emory University.
Dostarlimab Earns Priority Review From FDA In Advanced Endometrial Cancer
June 6th 2023The FDA accepts a supplemental biologics license application for dostarlimab plus chemotherapy in the treatment of mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer based on data from a prespecified interim analysis of the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial.
No Improvement in OS With Extended Vs Standard Lymphadenectomy in MIBC
June 6th 2023Findings from the phase 3 SWOG S1011 trial highlight no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.
LAG-3 Protein/Pembrolizumab Yield Encouraging Responses in Metastatic HNSCC
Treatment with eftilagimod alpha in combination with pembrolizumab appears safe and well tolerated among patients with metastatic head and neck squamous cell carcinoma in the phase 2 TACTI-002 study.
Cabozantinib Combo Does Not Improve Survival in Pretreated, Advanced RCC
Data from the phase 3 CONTACT-03 trial highlight the necessity of randomized, prospective assessment of re-challenge with checkpoint inhibitors in renal cell carcinoma, according to an expert from Dana-Farber Cancer Institute.
Cilta-Cel Improves PFS Vs SOC Regimen in Lenalidomide-Refractory Myeloma
Ciltacabtagene autoleucel may become a new standard of care for patients with lenalidomide-refractory myeloma after first relapse, according to an expert from the Medical College of Wisconsin in Milwaukee.
Lasofoxifene Combo Yields Meaningful Activity in ER+/HER2– Breast Cancer
June 6th 2023The anti-tumor activity of lasofoxifene plus abemaciclib does not appear to be compromised by co-occurring alterations that confer resistance among patients with estrogen receptor–positive HER2-negative breast cancer.
Fruquintinib/BSC Improves Survival Vs Placebo in Refractory mCRC
Fruquintinib plus best supportive care elicits a progression-free survival benefit across all prior treatment subgroups among patients with refractory metastatic colorectal cancer in the phase 3 FRESCO-2 trial.
Sacituzumab Govitecan Yields Enduring Survival in HR+, HER2– Breast Cancer
June 5th 2023Additionally, treatment with sacituzumab govitecan-hziy may result in a prolonged overall response rate and clinical benefit rate vs treatment of physician’s choice in pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.